Medicus Pharma Secures Improved Teverelix License Terms and Reports Promising Phase 1 Data in Women
核心洞察
Medicus Pharma (搜索) amended its LifeArc (搜索) license agreement for Teverelix, reducing royalty rates from approximately 4% to 2% while maintaining global development rights and intellectual property control.
Phase 1 clinical data from 48 healthy premenopausal women demonstrated rapid hormone suppression within 24 hours and stable bone turnover markers with no drug-related serious adverse events.
The company is advancing Teverelix development across multiple indications including prostate cancer, acute urinary retention relapse prevention, and women's health conditions like endometriosis.
Medicus Pharma (搜索) Ltd. has strengthened its position in the GnRH antagonist market through a significant amendment to its Teverelix licensing agreement and the presentation of encouraging Phase 1 clinical data demonstrating the drug's potential in women's health applications.
License Amendment Improves Economic Profile
The company's subsidiary, Antev (搜索) Ltd., has entered into Amendment No. 3 to its license agreement with LifeArc (搜索), reducing the royalty rate on worldwide net sales of Teverelix from approximately 4% to 2%. The amendment maintains the scope of the exclusive, worldwide license while preserving all development responsibilities and intellectual property rights.
"This amendment substantially improves the long-term economic profile of Teverelix while preserving the strength and integrity of the underlying license," stated Dr. Raza Bokhari, Medicus Executive Chairman & CEO. "We believe the reduced royalty burden enhances Teverelix's attractiveness for future partnering, especially for late-stage development and commercialization."
The original license grants exclusive worldwide rights to develop, manufacture, and commercialize Teverelix across all major global markets, with full rights to grant sublicenses through multiple tiers. Medicus maintains full operational control over development, manufacturing, and commercialization activities, while all program-specific improvements developed by the company remain under its ownership.
Phase 1 Data Shows Promise in Women's Health
Clinical data from two randomized, placebo-controlled Phase 1 studies involving 48 healthy premenopausal women have been accepted for presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026. The studies evaluated single subcutaneous doses of Teverelix at 30 mg, 45 mg, or 60 mg compared to placebo.
Key findings from the Phase 1 studies include rapid suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) within 24 hours of dosing. The treatment demonstrated dose-dependent and reversible estradiol suppression, with multiple participants achieving levels within the clinically relevant Barbieri window of 30-50 pg/mL, a range associated with symptom control while mitigating bone loss risk.
Sustained pharmacodynamic activity was observed, with hormone suppression lasting up to two to three weeks following a single injection at higher doses. Importantly, bone turnover markers remained stable, suggesting no evidence of short-term bone loss. The treatment showed a favorable safety profile with no drug-related serious adverse events and only mild-to-moderate treatment-emergent adverse events reported.
Expanding Therapeutic Applications
The Phase 1 results support Teverelix's potential advancement into endometriosis treatment, a condition affecting approximately 10% of women of reproductive age worldwide. Dr. Bokhari noted that controlled, reversible hormone suppression and bone safety are critical factors in this indication. The company is currently engaged in regulatory planning for a Phase 2, genomics-informed study of Teverelix in women with symptomatic endometriosis in the United Arab Emirates.
Teverelix trifluoroacetate is formulated as a long-acting injectable GnRH antagonist in microcrystalline suspension. Unlike GnRH agonists that induce an initial hormonal surge, Teverelix produces immediate receptor antagonism, enabling rapid suppression of LH, FSH, and downstream sex hormones without flare.
Market Opportunity and Development Strategy
The company is developing Teverelix as a first-in-class market product for acute urinary retention relapse prevention and best-in-class for prostate cancer patients with high cardiovascular risk, collectively representing approximately $6 billion in potential market opportunity.
This mechanism may be clinically relevant in advanced prostate cancer patients with elevated cardiovascular risk, where emerging evidence suggests persistent FSH exposure may contribute to adverse cardiovascular outcomes. Prior Teverelix studies have not demonstrated significant cardiovascular safety signals, though further clinical validation is required.
Medicus follows a development strategy focused on advancing select programs through Phase 2 proof-of-concept before pursuing licensing or strategic partnerships with established pharmaceutical companies for late-stage development and commercialization. The company continues to assemble decision-grade clinical and regulatory data packages across its portfolio to support this partnering-focused model.
Regulatory Progress and Future Plans
The FDA has provided written guidance on Antev (搜索)'s proposed Phase 3 trial design for Teverelix following review of Phase 1 and Phase 2a data in January 2023. In December 2023, the FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients, and in November 2024, approved the Phase 2b study design in acute urinary retention covering 390 patients.
Previous Phase 2a results in 50 patients with advanced prostate cancer showed Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression at 97.5%, though the secondary endpoint of maintaining this rate above 90% was not met, with the probability dropping to 82.5% by Day 42.